NEW YORK (GenomeWeb) – Invitae and Alnylam Pharmaceuticals have together launched a free genetic testing service for hereditary ATTR amyloidosis, called Alnylam Act, to encourage early testing and diagnosis for the disease.

Through this program, funded by Alnylam, Invitae will perform free testing using one of its comprehensive gene panels for cardiomyopathy, neuropathy, or amyloidosis. Patients eligible for free testing are those in the US who are suspected to have the disease or a family history of it.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.